Arecor Therapeutics PLC FIRST PATIENT DOSED IN AT278 CLINICAL TRIAL (7742T)
March 22 2023 - 3:00AM
UK Regulatory
TIDMAREC
RNS Number : 7742T
Arecor Therapeutics PLC
22 March 2023
Arecor Therapeutics plc
("Arecor" or the "Group")
FIRST PATIENT DOSED IN SECOND PHASE I CLINICAL TRIAL OF AT278
ULTRA-CONCENTRATED, ULTRA-RAPID ACTING INSULIN CANDIDATE
- Disrupter insulin with potential to be the first
ultra-concentrated and ultra-rapid acting insulin available for
patients
- AT278 aims to significantly improve post prandial glucose
control and reduce injection volume and potentially enable fewer
injections per day for people with Type 2 diabetes who have high
insulin needs
- Ultra-concentrated, ultra-rapid acting insulin such as AT278
is critical to development of next generation miniaturised insulin
delivery devices
- Trial expected to complete in Q4 2023
Cambridge, UK, 22 March 2023: Arecor Therapeutics plc (AIM:
AREC), the biopharmaceutical group advancing today's therapies to
enable healthier lives, today announces that the first patient has
been dosed in its Phase I clinical trial investigating AT278, an
ultra-rapid acting, ultra-concentrated (500 U/mL) insulin candidate
, in Type 2 diabetic patients, the primary target population.
The trial is a double blind, randomised, crossover study
comparing the pharmacokinetic (PK) and pharmacodynamic (PD) profile
following a single subcutaneous dose of 0.5 U/Kg of AT278 (500
U/mL) with NovoRapid(R) (100 U/mL) in 32 people with Type 2
diabetes in a euglycemic clamp setting. In addition, the PK/PD
profile following a single subcutaneous dose of 0.5 U/Kg Humulin-R
U500(R) will be evaluated in each of the participants. The trial,
which is expected to complete within Q4 2023, is being conducted at
the Medical University of Graz, Austria, an expert clinical
research facility in metabolic diseases research and euglycaemic
clamp methodology, with Professor Thomas Pieber as the trial's
Principal Investigator.
Sarah Howell, Chief Executive Officer at Arecor, said: "Having
already demonstrated AT278's very promising profile in Type 1
diabetes patients, we look forward to furthering our understanding
of its potential impact in Type 2 diabetes patients, the primary
target market for this potential insulin treatment.
"The number of people living with Type 2 diabetes is increasing
year-on-year and driven by the obesity epidemic, many are becoming
insulin resistant, requiring large volumes of insulin and multiple
injections to manage their condition, which is a heavy daily
burden. With no concentrated (>200 U/mL) rapid acting insulin
products on the market, AT278 could be the first such product
available to patients, enabling effective blood glucose management
alongside the convenience and compliance benefits of high insulin
doses in a lower injection volume via a single injection. In
addition, a truly rapid acting, concentrated insulin is a critical
step towards the advancement and miniaturisation of the next
generation of insulin delivery devices."
AT278, is an ultra-concentrated (500 U/mL) novel formulation of
insulin that has been designed to accelerate the absorption of
insulin post injection, even when delivered at a high
concentration, and hence via a lower injection volume. In the
previous Phase I clinical study in people with Type I diabetes,
AT278 clearly demonstrated faster insulin absorption with an
accelerated PK/PD profile compared to gold-standard insulin
NovoRapid(R) (100U/mL), despite a 5-fold increase in
concentration.
This announcement contains inside information for the purposes
of the UK Market Abuse Regulation.
-ENDS-
For more information, please contact:
Arecor Therapeutics plc www.arecor.com
Dr Sarah Howell, Chief Executive Tel: +44 (0) 1223 426060
Officer Email: info@arecor.com
Susan Lowther, Chief Financial Officer Tel: +44 (0) 1223 426060
Email: info@arecor.com
Mo Noonan, Communications Tel: +44 (0) 7876 444977
Email: mo.noonan@arecor.com
Panmure Gordon (UK) Limited (NOMAD
and Broker)
Freddy Crossley, Emma Earl (Corporate Tel: +44 (0) 20 7886 2500
Finance)
Rupert Dearden (Corporate Broking)
Consilium Strategic Communications
Chris Gardner, David Daley, Lindsey Tel: +44 (0) 20 3709 5700
Neville Email: arecor@consilium-comms.com
Notes to Editors
About Arecor
Arecor Therapeutics plc is a globally focused biopharmaceutical
group transforming patient care by bringing innovative medicines to
market through the enhancement of existing therapeutic products. By
applying our innovative proprietary formulation technology
platform, Arestat(TM), we are developing an internal portfolio of
proprietary products in diabetes and other indications, as well as
working with leading pharmaceutical and biotechnology companies to
deliver enhanced formulations of their therapeutic products. The
Arestat(TM) platform is supported by an extensive patent portfolio.
For further details please see our website, www.arecor.com
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
RESFLFITVVILFIV
(END) Dow Jones Newswires
March 22, 2023 03:00 ET (07:00 GMT)
Arecor Therapeutics (LSE:AREC)
Historical Stock Chart
From Jul 2024 to Aug 2024
Arecor Therapeutics (LSE:AREC)
Historical Stock Chart
From Aug 2023 to Aug 2024